Published in Immunology on January 01, 1988
C3bi-binding protein on Candida albicans: temperature-dependent expression and relationship to human complement receptor type 3. Infect Immun (1989) 1.76
Relationship between high-grade lymphoma and low-grade B-cell mucosa-associated lymphoid tissue lymphoma (MALToma) of the stomach. Am J Pathol (1990) 1.59
Laser-capture microdissection of oropharyngeal epithelium indicates restriction of Epstein-Barr virus receptor/CD21 mRNA to tonsil epithelial cells. J Oral Pathol Med (2008) 1.00
Determination of soluble CD21 as a parameter of B cell activation. Clin Exp Immunol (1993) 0.89
Extensive complement-dependent enhancement of HIV-1 by autologous non-neutralising antibodies at early stages of infection. Retrovirology (2011) 0.85
Development, maturation and subsequent activation of follicular dendritic cells (FDC): immunohistochemical observation of human fetal and adult lymph nodes. Histochem Cell Biol (2006) 0.78
Diffuse lymphocyte-predominant Hodgkin's disease (diffuse paragranuloma). A variant of the B-cell-derived nodular type. Am J Pathol (1991) 0.76
Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature (1970) 1528.65
Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proc Natl Acad Sci U S A (1979) 365.71
Protein and cell membrane iodinations with a sparingly soluble chloroamide, 1,3,4,6-tetrachloro-3a,6a-diphrenylglycoluril. Biochem Biophys Res Commun (1978) 32.33
Ultrasensitive stain for proteins in polyacrylamide gels shows regional variation in cerebrospinal fluid proteins. Science (1981) 23.67
The use of avidin-biotin interaction in immunoenzymatic techniques. J Histochem Cytochem (1979) 9.06
Epstein-Barr virus receptor of human B lymphocytes is the C3d receptor CR2. Proc Natl Acad Sci U S A (1984) 6.62
Identification of the membrane glycoprotein that is the C3b receptor of the human erythrocyte, polymorphonuclear leukocyte, B lymphocyte, and monocyte. J Exp Med (1980) 6.49
Identification and characterization of the Epstein-Barr virus receptor on human B lymphocytes and its relationship to the C3d complement receptor (CR2). J Virol (1985) 3.76
Characterization of a human B cell-specific antigen (B2) distinct from B1. J Immunol (1981) 2.86
Membrane complement receptors specific for bound fragments of C3. Adv Immunol (1985) 2.80
Identification of a 145,000 Mr membrane protein as the C3d receptor (CR2) of human B lymphocytes. Proc Natl Acad Sci U S A (1984) 2.71
Identification of the membrane receptor for the complement fragment C3d by means of a monoclonal antibody. J Exp Med (1983) 2.31
Molecular cloning and characterization of the cDNA coding for C4b-binding protein, a regulatory protein of the classical pathway of the human complement system. Biochem J (1985) 2.19
gp140, the C3d receptor of human B lymphocytes, is also the Epstein-Barr virus receptor. Proc Natl Acad Sci U S A (1985) 2.07
Expression of C3d receptors during human B cell differentiation: immunofluorescence analysis with the HB-5 monoclonal antibody. J Immunol (1984) 2.06
Growth control of activated, synchronized murine B cells by the C3d fragment of human complement. Nature (1985) 1.98
A complement receptor locus: genes encoding C3b/C4b receptor and C3d/Epstein-Barr virus receptor map to 1q32. J Immunol (1987) 1.94
Epstein-Barr virus receptors on human pharyngeal epithelia. Lancet (1986) 1.88
Isolation of lymphocyte membrane complement receptor type two (the C3d receptor) and preparation of receptor-specific antibody. Proc Natl Acad Sci U S A (1981) 1.86
A second site for Epstein-Barr virus shedding: the uterine cervix. Lancet (1986) 1.61
Enhancement of human B cell proliferation by an antibody to the C3d receptor, the gp 140 molecule. Eur J Immunol (1985) 1.60
Binding of monoclonal antibody to the Epstein Barr virus (EBV)/CR2 receptor induces activation and differentiation of human B lymphocytes. J Immunol (1985) 1.58
Analysis of C3-receptor activity on human B-lymphocytes and isolation of the complement receptor type 2 (CR2). Biochem J (1984) 1.51
Identification of a partial cDNA clone for the C3d/Epstein-Barr virus receptor of human B lymphocytes: homology with the receptor for fragments C3b and C4b of the third and fourth components of complement. Proc Natl Acad Sci U S A (1986) 1.42
Isolation and characterization of a C3b receptor-like molecule from membranes of a human B lymphoblastoid cell line (Raji). FEBS Lett (1981) 1.24
Structural and functional analysis of the complement component factor H with the use of different enzymes and monoclonal antibodies to factor H. Biochem J (1985) 1.24
Use of monoclonal antibodies against factor H to investigate the role of a membrane-associated protein antigenically related to H in C3b-receptor function. J Immunol (1984) 1.12
The action of human C3 in soluble or cross-linked form with resting and activated murine B lymphocytes. Eur J Immunol (1985) 1.03
Role of beta 1H for the binding of C3b-coated particles to human lymphoid and phagocytic cells. Eur J Immunol (1981) 0.91
Human complement factor H: isolation of cDNA clones and partial cDNA sequence of the 38-kDa tryptic fragment containing the binding site for C3b. Eur J Immunol (1986) 0.90
Enzyme-linked immunoassay to monitor the purification of, and to screen for monoclonal antibodies against, C3b receptor. Complement (1985) 0.82
The generation of active fragments of complement receptor type 2 by trypsin digestion. FEBS Lett (1985) 0.81
Kaposi's sarcoma-associated herpesvirus infects endothelial and spindle cells. Nat Med (1995) 6.71
Prevalence of Kaposi's sarcoma associated herpesvirus infection measured by antibodies to recombinant capsid protein and latent immunofluorescence antigen. Lancet (1996) 4.05
The V3 loops of the HIV-1 and HIV-2 surface glycoproteins contain proteolytic cleavage sites: a possible function in viral fusion? AIDS Res Hum Retroviruses (1991) 3.78
Neopterin as a marker for activated cell-mediated immunity: application in HIV infection. Immunol Today (1988) 3.13
Enhancement of sheep red blood cell human lymphocyte rosette formation by the sulfhydryl compound 2-amino ethylisothiouronium bromide. Clin Immunol Immunopathol (1975) 3.11
Latent nuclear antigen of Kaposi's sarcoma-associated herpesvirus interacts with RING3, a homolog of the Drosophila female sterile homeotic (fsh) gene. J Virol (1999) 2.36
In-vitro testing of susceptibility to amphotericin B is a reliable predictor of clinical outcome in invasive aspergillosis. J Antimicrob Chemother (1998) 2.32
Candida albicans and Candida stellatoidea, in contrast to other Candida species, bind iC3b and C3d but not C3b. Infect Immun (1985) 2.25
Third component of complement (C3): structural properties in relation to functions. Proc Natl Acad Sci U S A (1975) 2.21
Detection of human herpesvirus 8 DNA in semen from HIV-infected individuals but not healthy semen donors. AIDS (1997) 2.20
Expression and modulation of CD44 variant isoforms in humans. J Cell Biol (1994) 2.17
Risk factors for human herpesvirus 8 seropositivity and seroconversion in a cohort of homosexual men. Am J Epidemiol (2000) 2.05
Growth control of activated, synchronized murine B cells by the C3d fragment of human complement. Nature (1985) 1.98
Kaposi's sarcoma in the Gambia, West Africa is less frequent in human immunodeficiency virus type 2 than in human immunodeficiency virus type 1 infection despite a high prevalence of human herpesvirus 8. J Hum Virol (1999) 1.90
Interassay correlation of human herpesvirus 8 serologic tests. HHV-8 Interlaboratory Collaborative Group. J Infect Dis (1998) 1.79
Strain-specific differences in the amount of Shiga toxin released from enterohemorrhagic Escherichia coli O157 following exposure to subinhibitory concentrations of antimicrobial agents. Eur J Clin Microbiol Infect Dis (1998) 1.77
C3bi-binding protein on Candida albicans: temperature-dependent expression and relationship to human complement receptor type 3. Infect Immun (1989) 1.76
Transcomplementation of VIF- HIV-1 mutants in CEM cells suggests that VIF affects late steps of the viral life cycle. Virology (1993) 1.74
Human immunodeficiency virus type 1 activates the classical pathway of complement by direct C1 binding through specific sites in the transmembrane glycoprotein gp41. J Exp Med (1991) 1.71
Identification of a spliced gene from Kaposi's sarcoma-associated herpesvirus encoding a protein with similarities to latent membrane proteins 1 and 2A of Epstein-Barr virus. J Virol (1999) 1.66
Bone marrow failure associated with human herpesvirus 8 infection after transplantation. N Engl J Med (2000) 1.64
Prevalence and transmission of Kaposi's sarcoma-associated herpesvirus (human herpesvirus 8) in Ugandan children and adolescents. Int J Cancer (1998) 1.61
Qualitative and quantitative assessment of C3-receptor reactivities on lymphoid and phagocytic cells. J Immunol (1981) 1.57
Distribution of human endogenous retrovirus HERV-K genomes in humans and different primates. Hum Genet (1995) 1.52
[Vancomycin resistant enterococci in Austria]. Wien Klin Wochenschr (1997) 1.51
Studies of in vitro activities of voriconazole and itraconazole against Aspergillus hyphae using viability staining. Antimicrob Agents Chemother (2001) 1.50
Impact of adjunct cytogenetic abnormalities for prognostic stratification in patients with myelodysplastic syndrome and deletion 5q. Leukemia (2010) 1.48
Structural requirements for C3d,g/Epstein-Barr virus receptor (CR2/CD21) ligand binding, internalization, and viral infection. J Biol Chem (1990) 1.48
First Neisseria gonorrhoeae strain with resistance to cefixime causing gonorrhoea treatment failure in Austria, 2011. Euro Surveill (2011) 1.48
Mycosis fungoides and Sezary syndrome are not associated with HTLV-I infection: an international study. Br J Haematol (1997) 1.47
Adult T-cell leukaemia/lymphoma in Brazil and its relation to HTLV-I. Lancet (1990) 1.47
Recombinant versus plasma-derived hepatitis B vaccine: comparison of immunogenicity in medical students. Vaccine (1992) 1.47
Acquisition of host cell-surface-derived molecules by HIV-1. AIDS (1996) 1.46
Molecular epidemiology of Klebsiella pneumoniae producing SHV-5 beta- lactamase: parallel outbreaks due to multiple plasmid transfer. J Clin Microbiol (1996) 1.45
Cytokine-induced generation of multinucleated giant cells in vitro requires interferon-gamma and expression of LFA-1. Eur J Immunol (1990) 1.44
Localization of the complement-component-C3b-binding site and the cofactor activity for factor I in the 38kDa tryptic fragment of factor H. Biochem J (1984) 1.44
Two distinct gamma-2 herpesviruses in African green monkeys: a second gamma-2 herpesvirus lineage among old world primates? J Virol (2000) 1.44
Comorbidity as prognostic variable in MDS: comparative evaluation of the HCT-CI and CCI in a core dataset of 419 patients of the Austrian MDS Study Group. Ann Oncol (2009) 1.43
Human macrophages degrade tryptophan upon induction by interferon-gamma. Life Sci (1987) 1.42
Antifungal properties of selective serotonin reuptake inhibitors against Aspergillus species in vitro. J Antimicrob Chemother (2001) 1.42
Reducing HIV transmission by seronegative blood. Lancet (1992) 1.41
The C-terminus of factor H: monoclonal antibodies inhibit heparin binding and identify epitopes common to factor H and factor H-related proteins. Biochem J (1998) 1.40
A new kind of orphan drug? Nature (1992) 1.38
Demonstration of binding sites for IgG Fc and the third complement component (C3) on isolated hepatocytes. J Immunol (1976) 1.36
Specificity of membrane complement receptor type three (CR3) for beta-glucans. Complement (1987) 1.35
Seroconversion for human herpesvirus 8 during HIV infection is highly predictive of Kaposi's sarcoma. AIDS (1998) 1.34
Urinary tract infection caused by nontyphoidal Salmonella: report of 30 cases. Urol Int (1992) 1.33
Enzyme-linked immunosorbent assay for detection of T-2 toxin. Hoppe Seylers Z Physiol Chem (1982) 1.33
Human immunodeficiency virus type 1 gp160 and gp41 binding to Candida albicans selectively enhances candidal virulence in vitro. J Infect Dis (1998) 1.31
Expression of 7F7-antigen, a human adhesion molecule identical to intercellular adhesion molecule-1 (ICAM-1) in human carcinomas and their stromal fibroblasts. Int J Cancer (1989) 1.31
Dyslipoproteinemia in the course of active rheumatoid arthritis. Semin Arthritis Rheum (1992) 1.31
Simultaneous infection with two drug-susceptible Mycobacterium tuberculosis strains in an immunocompetent host. J Clin Microbiol (1999) 1.29
Antifungal activity against Candida species of the selective serotonin-reuptake inhibitor, sertraline. Clin Infect Dis (2001) 1.29
HIV-1 gp41 contains two sites for interaction with several proteins on the helper T-lymphoid cell line, H9. AIDS (1992) 1.29
Screening for Aspergillus spp. using polymerase chain reaction of whole blood samples from patients with haematological malignancies. Br J Haematol (2001) 1.27
Survival, prognostic factors and rates of leukemic transformation in 381 untreated patients with MDS and del(5q): a multicenter study. Leukemia (2012) 1.27
The human herpesvirus-8 ORF 57 gene and its properties. J Gen Virol (1999) 1.25
Risk factors for Kaposi's-sarcoma-associated herpesvirus (KSHV/HHV-8) seropositivity in a cohort of homosexual men, 1981-1996. Int J Cancer (1998) 1.25
In vitro activity of fosfomycin in combination with various antistaphylococcal substances. J Antimicrob Chemother (2001) 1.24
Structural and functional analysis of the complement component factor H with the use of different enzymes and monoclonal antibodies to factor H. Biochem J (1985) 1.24
Efficient destruction of human immunodeficiency virus in human serum by inhibiting the protective action of complement factor H and decay accelerating factor (DAF, CD55). J Exp Med (1996) 1.23
Prognostic impact of age and gender in 897 untreated patients with primary myelodysplastic syndromes. Ann Oncol (2009) 1.22
Comparative study of five different techniques for epidemiological typing of Escherichia coli O157. Diagn Microbiol Infect Dis (1998) 1.22
Aspergillus terreus infections in haematological malignancies: molecular epidemiology suggests association with in-hospital plants. J Hosp Infect (2000) 1.21
Evaluation of C3 receptors on lymphoid cells with different complement sources. J Immunol (1974) 1.19
Role of complement in HIV infection. Annu Rev Immunol (1997) 1.18
Regulation of the expression of ICAM-1 on human monocytes and monocytic tumor cell lines. J Immunol (1992) 1.17
Variability and evolution of Kaposi's sarcoma-associated herpesvirus in Europe and Africa. International Collaborative Group. AIDS (1999) 1.17
Essential role of surface-bound chemoattractant in leukocyte migration. Nature (1977) 1.15
Increased endogenous interferon-gamma and neopterin correlate with increased degradation of tryptophan in human immunodeficiency virus type 1 infection. Immunol Lett (1991) 1.14
Interferon-gamma concentrations are increased in sera from individuals infected with human immunodeficiency virus type 1. J Acquir Immune Defic Syndr (1989) 1.14
Neopterin modulates toxicity mediated by reactive oxygen and chloride species. FEBS Lett (1993) 1.14
Complement-mediated enhancement of HIV-1 infection of the monoblastoid cell line U937. AIDS (1990) 1.13
Analysis of bypass activation of C3 by endotoxic LPS and loss of this potency. Immunology (1973) 1.13
Decay-accelerating factor (CD55) protects human immunodeficiency virus type 1 from inactivation by human complement. Eur J Immunol (1995) 1.12
Isolation and biochemical characterization of the iC3b receptor of Candida albicans. Infect Immun (1993) 1.12
Use of monoclonal antibodies against factor H to investigate the role of a membrane-associated protein antigenically related to H in C3b-receptor function. J Immunol (1984) 1.12
Activation of human monocytes by both human beta 1H and C3b. Immunology (1982) 1.11
Detachment of human immunodeficiency virus type 1 from germinal centers by blocking complement receptor type 2. J Virol (2000) 1.11
High risk of developing toxoplasmic encephalitis in AIDS patients seropositive to Toxoplasma gondii. Med Microbiol Immunol (1991) 1.11
Uncaria tomentosa (Willd.) DC.--ethnomedicinal use and new pharmacological, toxicological and botanical results. J Ethnopharmacol (1999) 1.11
Are CD44 variant isoforms involved in human tumour progression? Cancer Surv (1995) 1.10
Listeria monocytogenes cholecystitis. Z Gastroenterol (1989) 1.10
Kaposi's sarcoma-associated herpesvirus serology in Europe and Uganda: multicentre study with multiple and novel assays. J Med Virol (2001) 1.10
A novel mechanism of alternative pathway complement activation accounts for the deposition of C3 fragments on CR2-expressing homologous cells. J Immunol (1997) 1.10
Seroprevalence of Kaposi's sarcoma-associated herpesvirus/human herpesvirus 8 in several regions of Italy. J Hum Virol (1999) 1.09
Factor D in the alternate pathway of complement activation: purification, physicochemical characterization and functional role. Immunochemistry (1974) 1.09
Reduced seroprevalence of Kaposi's sarcoma-associated herpesvirus (KSHV), human herpesvirus 8 (HHV8), related to suppression of Anopheles density in Italy. Med Vet Entomol (2003) 1.08
Complement bridges between cells analysis of a possible cell-cell interaction mechanism. J Exp Med (1977) 1.08
Antibodies in human sera recognizing a recombinant outer membrane protein encoded by the envelope gene of the human endogenous retrovirus K. AIDS Res Hum Retroviruses (1993) 1.08